These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

454 related items for PubMed ID: 21203982

  • 1. Molecular and cellular bases of chronic myeloid leukemia.
    Chen Y, Peng C, Li D, Li S.
    Protein Cell; 2010 Feb; 1(2):124-32. PubMed ID: 21203982
    [Abstract] [Full Text] [Related]

  • 2. BCR-ABL kinase is dead; long live the CML stem cell.
    Perl A, Carroll M.
    J Clin Invest; 2011 Jan; 121(1):22-5. PubMed ID: 21157035
    [Abstract] [Full Text] [Related]

  • 3. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.
    Hu Y, Swerdlow S, Duffy TM, Weinmann R, Lee FY, Li S.
    Proc Natl Acad Sci U S A; 2006 Nov 07; 103(45):16870-5. PubMed ID: 17077147
    [Abstract] [Full Text] [Related]

  • 4. Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia.
    Giles FJ, Cortes JE, Kantarjian HM.
    Curr Mol Med; 2005 Nov 07; 5(7):615-23. PubMed ID: 16305488
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells.
    Mak DH, Schober WD, Chen W, Konopleva M, Cortes J, Kantarjian HM, Andreeff M, Carter BZ.
    Mol Cancer Ther; 2009 Sep 07; 8(9):2509-16. PubMed ID: 19723894
    [Abstract] [Full Text] [Related]

  • 11. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
    Wolff NC, Veach DR, Tong WP, Bornmann WG, Clarkson B, Ilaria RL.
    Blood; 2005 May 15; 105(10):3995-4003. PubMed ID: 15657179
    [Abstract] [Full Text] [Related]

  • 12. A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia.
    Ma L, Shan Y, Bai R, Xue L, Eide CA, Ou J, Zhu LJ, Hutchinson L, Cerny J, Khoury HJ, Sheng Z, Druker BJ, Li S, Green MR.
    Sci Transl Med; 2014 Sep 03; 6(252):252ra121. PubMed ID: 25186176
    [Abstract] [Full Text] [Related]

  • 13. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop.
    Roumiantsev S, Shah NP, Gorre ME, Nicoll J, Brasher BB, Sawyers CL, Van Etten RA.
    Proc Natl Acad Sci U S A; 2002 Aug 06; 99(16):10700-5. PubMed ID: 12149456
    [Abstract] [Full Text] [Related]

  • 14. Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia.
    Kim TD, Türkmen S, Schwarz M, Koca G, Nogai H, Bommer C, Dörken B, Daniel P, le Coutre P.
    Haematologica; 2010 Apr 06; 95(4):582-8. PubMed ID: 20015884
    [Abstract] [Full Text] [Related]

  • 15. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors.
    Copland M, Pellicano F, Richmond L, Allan EK, Hamilton A, Lee FY, Weinmann R, Holyoake TL.
    Blood; 2008 Mar 01; 111(5):2843-53. PubMed ID: 18156496
    [Abstract] [Full Text] [Related]

  • 16. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
    Lernoux M, Schnekenburger M, Losson H, Vermeulen K, Hahn H, Gérard D, Lee JY, Mazumder A, Ahamed M, Christov C, Kim DW, Dicato M, Bormans G, Han BW, Diederich M.
    Clin Epigenetics; 2020 May 19; 12(1):69. PubMed ID: 32430012
    [Abstract] [Full Text] [Related]

  • 17. The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias.
    Maekawa T, Ashihara E, Kimura S.
    Int J Clin Oncol; 2007 Oct 19; 12(5):327-40. PubMed ID: 17929114
    [Abstract] [Full Text] [Related]

  • 18. Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapy.
    Abe A, Minami Y, Hayakawa F, Kitamura K, Nomura Y, Murata M, Katsumi A, Kiyoi H, Jamieson CHM, Wang JYJ, Naoe T.
    Int J Hematol; 2008 Dec 19; 88(5):471-475. PubMed ID: 19039626
    [Abstract] [Full Text] [Related]

  • 19. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
    He B, Wang Q, Liu X, Lu Z, Han J, Pan C, Carter BZ, Liu Q, Xu N, Zhou H.
    Biomed Pharmacother; 2020 Sep 19; 129():110390. PubMed ID: 32563150
    [Abstract] [Full Text] [Related]

  • 20. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
    Chu S, Holtz M, Gupta M, Bhatia R.
    Blood; 2004 Apr 15; 103(8):3167-74. PubMed ID: 15070699
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.